About 33,883 results

ALLMedicine™ Systemic Lupus Erythematosus Center

Research & Reviews  11,196 results

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Prot...
Journal of Visualized Experiments : JoVE; Cabana-Puig X, Luo XM

Jun 28th, 2022 - Systemic lupus erythematosus (SLE) is an autoimmune disorder with no known cure and is characterized by persistent inflammation in many organs, including the kidneys. Under such circumstances, the kidney loses its ability to clean waste from the b...

Multi-trait and cross-population genome-wide association studies across autoimmune and ...
Annals of the Rheumatic Diseases; Shirai Y, Nakanishi Y et. al.

Jun 27th, 2022 - Autoimmune and allergic diseases are outcomes of the dysregulation of the immune system. Our study aimed to elucidate differences or shared components in genetic backgrounds between autoimmune and allergic diseases. We estimated genetic correlatio...

A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, System...
https://doi.org/10.1007/s12016-022-08951-z 10.1038/nm.3897 10.1016/j.jaut.2009.09.008 10.1016/j.autrev.2012.02.001 10.1038/nrdp.2015.2 10.1016/S0140-6736(17)30933-9 10.3389/fimmu.2020.606936 10.1002/art.1780350310 10.1002/art.11173 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B 10.1002/art.20999 10.1186/gm305 10.1002/art.1780200501 10.1056/NEJM197804202981602 10.1002/acr2.11065 10.1016/j.ajhg.2012.08.026 10.1111/j.1744-313X.2012.01145.x 10.1002/art.39504 10.1093/hmg/ddy280 10.1038/ncomms6902 10.1038/ng.3496 10.1002/anr.1780320410 10.1371/journal.pgen.1008092 10.1002/art.41610 10.1136/annrheumdis-2018-214323 10.1136/annrheumdis-2021-219884 10.1093/rheumatology/key281 10.1073/pnas.1906593116 10.1136/ard.2009.111906 10.1093/rheumatology/ker335 10.1371/journal.pone.0126727 10.1136/annrheumdis-2016-210645 10.3899/jrheum.110071 10.1016/j.ajhg.2013.12.002 10.1371/journal.pgen.1002178 10.1038/s41467-019-12760-y 10.1038/ng.1076 10.1016/j.ajhg.2014.02.013 10.1016/j.ajhg.2016.06.019 10.1001/jama.2015.3435 10.1016/j.ajhg.2019.09.018 10.1186/s13075-021-02431-z 10.1186/ar3204 10.1093/nar/gky1120 10.1146/annurev.immunol.22.012703.104549 10.1177/0961203317735187 10.1002/art.10438 10.1086/428480 10.1038/ng1782 10.1073/pnas.0701266104 10.1093/hmg/ddu455 10.1086/422827 10.1086/423790 10.1056/NEJMoa073003 10.1093/hmg/ddy140 10.1136/annrheumdis-2017-212794 10.1056/NEJMoa0707865 10.1038/ng.79 10.1038/ng.71 10.1002/art.30563 10.1038/ng.3434 10.1038/s41423-019-0254-9 10.1371/journal.pone.0156302 10.1093/hmg/ddp118 10.1136/ard.2009.120543 10.1371/journal.pone.0084450 10.1038/s41588-018-0102-3 10.1038/gene.2011.84 10.1002/art.24436 10.1038/s41467-020-20460-1 10.3389/fimmu.2019.02160 10.1038/s41586-022-04642-z 10.1038/ncomms16021 10.1038/ng.565 10.1371/journal.pgen.1002091 10.1038/s41588-018-0108-x 10.1007/s00281-015-0499-z 10.1093/hmg/dds099 10.1136/ard.2009.127928 10.1186/s13075-014-0438-8 10.1136/annrheumdis-2020-218558 10.1038/sj.ejhg.5201423 10.1038/ng1206 10.1038/nature05911 10.1038/ng.2007.27 10.1056/NEJMoa073491 10.1002/art.23623 10.1038/ng.395 10.1038/ng.2462 10.1038/ng.2231 10.1038/ng.582 10.1038/nature12873 10.1136/annrheumdis-2013-204749 10.2119/molmed.2014.00097 10.1136/annrheumdis-2020-219065 10.1093/hmg/ddy395 10.1136/annrheumdis-2020-217663 10.1136/annrheumdis-2020-217351 10.1038/ng.2232 10.1038/ng.3406 10.1186/ar578 10.1093/ije/dyv136 10.1136/annrheumdis-2013-204173 10.1136/annrheumdis-2013-204133 10.1136/annrheumdis-2013-205009 10.1371/journal.pone.0024380 10.1093/rheumatology/kez638 10.1186/s13075-020-02253-5 10.1002/art.41517 10.1186/s13075-020-2134-1 10.1038/ng.2792 10.1007/s00439-016-1716-0 10.1002/art.40040 10.1371/journal.pgen.1006820 10.1038/nrendo.2013.161 10.1038/nrg2489 10.1002/art.39730 10.1186/s13073-018-0604-8 10.1136/annrheumdis-2019-215533 10.1038/nrrheum.2017.220 10.1007/s00281-021-00894-5 10.1038/nrrheum.2018.31 10.1136/ard.2011.150326 10.1172/JCI120288 10.3389/fimmu.2019.01029 10.1038/ng.975 10.1073/pnas.1815031116 10.1136/annrheumdis-2020-218810 10.1002/art.34642 10.1084/jem.20102177
Clinical Reviews in Allergy & Immunology; Ortíz-Fernández L, Martín J et. al.

Jun 25th, 2022 - Systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren's syndrome are four major autoimmune rheumatic diseases characterized by the presence of autoantibodies, caused by a dysregulation of the immune system that leads ...

Potential shared therapeutic and hepatotoxic mechanisms of Tripterygium wilfordii polyg...
Journal of Ethnopharmacology; Chen Y, Wang YF et. al.

Jun 25th, 2022 - Tripterygium wilfordii polyglycosides (TWP) are extracted from Tripterygium wilfordii Hook. f., which has the significant effects of anti-inflammation and immunosuppression and has been widely used to treat autoimmune diseases in traditional Chine...

Predictive model of risk and severity of enteritis in systemic lupus erythematosus.
Lupus Zhang W, Huang G et. al.

Jun 25th, 2022 - To describe the clinical and laboratory features of systemic lupus erythematosus (SLE) enteritis and to establish a predictive model of risk and severity of lupus enteritis (LE). Records of patients with SLE complaining about acute digestive sympt...

see more →

Guidelines  11 results

The significance of the low sex ratios of offspring and of sibs of probands with system...
Early Human Development; James WH, Grech V

Sep 8th, 2019 - There is good evidence that there are significantly low sex ratios (proportions male) in the offspring of patients with some immune diseases e.g. systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). There is also strong evidence that ...

2019 update of the EULAR recommendations for the management of systemic lupus erythemat...
Annals of the Rheumatic Diseases; Fanouriakis A, Kostopoulou M et. al.

Mar 31st, 2019 - Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to f...

First Latin American clinical practice guidelines for the treatment of systemic lupus e...
Annals of the Rheumatic Diseases; Pons-Estel BA, Bonfa E et. al.

Jul 27th, 2018 - Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therap...

The British Society for Rheumatology guideline for the management of systemic lupus ery...
Rheumatology (Oxford, England); Gordon C, Amissah-Arthur MB et. al.

Oct 14th, 2017 - The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary.|2017|Gordon C,Amissah-Arthur MB,Gayed M,Brown S,Bruce IN,|diagnosis,immunology,therapy,

The British Society for Rheumatology guideline for the management of systemic lupus ery...
Rheumatology (Oxford, England); Gordon C, Amissah-Arthur MB et. al.

Oct 14th, 2017 - The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults.|2017|Gordon C,Amissah-Arthur MB,Gayed M,Brown S,Bruce IN,|diagnosis,therapy,standards,standards,

see more →

Drugs  352 results see all →

Clinicaltrials.gov  714 results

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

Jun 24th, 2022 - OBJECTIVE: The objective of this study is to investigate whether there is a correlation between genetic mutations, beginning with an analysis of ABCA4, and Plaquenil -induced retinal toxicity and to describe the phenotype of Plaquenil -induced ret...

The Lupus prEGnAnCY Cohort: An International Prospective Cohort of Lupus Pregnancies

Jun 24th, 2022 - Systemic lupus erythematosus (SLE) predominantly affects women during their reproductive years. As SLE is associated with substantial fetal and maternal morbidity during pregnancy and beyond it is crucial to identify predictors of adverse pregnanc...

Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus

Jun 24th, 2022 - Study Design: This is a study of the acute effects of glucocorticoids on the immune system of patients with SLE. Participants will undergo baseline blood collection prior to receiving a single intravenous (IV) dose of methylprednisolone sodium suc...

Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients

Jun 24th, 2022 - Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with a relatively high mortality and morbidity rate, especially in developing countries such as Indonesia. In Indonesia, a previous study demonstrated that almost 71% of S...

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

Jun 24th, 2022 - Approximately 156 participants will be enrolled to receive daxdilimab administered subcutaneously over 48 weeks. The maximum trial duration per participant is approximately 56 weeks, including the 48 weeks for the open-label treatment period where...

see more →

News  1,269 results

Azathioprine Discontinuation Linked to Genotype Regardless of Race

Jun 21st, 2022 - NEW YORK (Reuters Health) - Across multiple disease settings, patients with the rs2814778-CC genotype face a higher risk of stopping azathioprine due to hematopoietic toxicity and receiving lower doses of thiopurines, regardless of race, a new stu...

New Blood Tests Approved for Lupus, Systemic Sclerosis Diagnoses

Jun 17th, 2022 - The Food and Drug Administration has approved a new diagnostic blood test to detect monospecific Ribosomal P antibodies to support a diagnosis of systemic lupus erythematosus (SLE), particularly for people who are antinuclear antibody-negative, ac...

Autoimmune disease linked to better late-stage breast cancer survival
Jim Kling

Jun 14th, 2022 - CHICAGO – Comorbid autoimmune disease is associated with a greater chance of survival among women with stage IV breast cancer, according to a retrospective study presented at the annual meeting of the American Society of Clinical Oncology. “It’s c.

Deucravacitinib and orelabrutinib perform well in early lupus trials
Sara Freeman

Jun 10th, 2022 - Deucravacitinib and orelabrutinib – two novel oral drugs under investigation for the treatment of systemic lupus erythematosus (SLE) – have performed well in early clinical trials reported as late-breaking abstracts at the annual European Congress.

Deucravacitinib and Orelabrutinib Perform Well in Lupus Trials

Jun 10th, 2022 - Deucravacitinib and orelabrutinib — two novel oral drugs under investigation for the treatment of systemic lupus erythematosus (SLE) — have performed well in early clinical trials reported as late-breaking abstracts at the annual European Congress...

see more →

Patient Education  11 results see all →